NAS:PRAH (USA) Also trade in: Germany

PRA Health Sciences Inc

$ 98.53 0 (0%)
Volume: 629,673 Avg Vol (1m): 610,411
Market Cap $: 6.47 Bil Enterprise Value $: 7.38 Bil
P/E (TTM): 41.22 P/B: 5.93
Earnings Power Value 11.34
Net Current Asset Value -22.01
Tangible Book -16.16
Projected FCF 38.25
Median P/S Value 89.15
Graham Number 0
Peter Lynch Value 59.75
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 5/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.16
Cash-To-Debt ranked lower than
90.42% of 261 companies
in the Diagnostics & Research industry.
Industry Max: 32990, Med: 3.52, Min: 0.01
PRAH: 0.16
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.04, Med: 0.11, Max: 0.24
Current: 0.16
0.04
0.24
Equity-to-Asset 0.32
Equity-to-Asset ranked lower than
87.03% of 239 companies
in the Diagnostics & Research industry.
Industry Max: 0.97, Med: 0.61, Min: -2.81
PRAH: 0.32
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.18, Med: 0.31, Max: 0.35
Current: 0.32
0.18
0.35
Debt-to-Equity 0.98
Debt-to-Equity ranked lower than
87.20% of 164 companies
in the Diagnostics & Research industry.
Industry Max: 22.86, Med: 0.36, Min: 0.01
PRAH: 0.98
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: 0.98, Med: 1.33, Max: 3
Current: 0.98
0.98
3
Debt-to-EBITDA 2.70
Debt-to-EBITDA ranked lower than
85.34% of 116 companies
in the Diagnostics & Research industry.
Industry Max: 77.72, Med: 1.77, Min: 0.03
PRAH: 2.7
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: 2.7, Med: 4.47, Max: 6.03
Current: 2.7
2.7
6.03
Interest Coverage 5.25
Interest Coverage ranked lower than
85.89% of 163 companies
in the Diagnostics & Research industry.
Industry Max: 15605.52, Med: 76.01, Min: 0.54
PRAH: 5.25
Ranked among companies with meaningful Interest Coverage only.
Interest Coverage range over the past 10 years
Min: 0.69, Med: 2.82, Max: 5.25
Current: 5.25
0.69
5.25
Piotroski F-Score 7
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 2.89
DISTRESS
GREY
SAFE
Beneish M-Score -2.78
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 9.37%
WACC 10.22%

Profitability & Growth : 6/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 9.97
Operating Margin ranked higher than
63.22% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 53.36, Med: -0.59, Min: -70300
PRAH: 9.97
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: 3.89, Med: 8.41, Max: 10.22
Current: 9.97
3.89
10.22
Net Margin % 5.50
Net Margin ranked higher than
64.32% of 241 companies
in the Diagnostics & Research industry.
Industry Max: 41.13, Med: -2.48, Min: -119600
PRAH: 5.5
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -2.45, Med: 3.81, Max: 5.5
Current: 5.5
-2.45
5.5
ROE % 15.86
ROE ranked higher than
71.07% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 61.7, Med: -6.75, Min: -12038.19
PRAH: 15.86
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -6.25, Med: 10, Max: 15.86
Current: 15.86
-6.25
15.86
ROA % 4.84
ROA ranked higher than
65.65% of 262 companies
in the Diagnostics & Research industry.
Industry Max: 1174.65, Med: -4.54, Min: -1248.4
PRAH: 4.84
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -1.55, Med: 3.11, Max: 4.84
Current: 4.84
-1.55
4.84
ROC (Joel Greenblatt) % 189.13
ROC (Joel Greenblatt) ranked higher than
95.75% of 259 companies
in the Diagnostics & Research industry.
Industry Max: 17601.65, Med: -9.57, Min: -3842027.78
PRAH: 189.13
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: 76.42, Med: 171.06, Max: 214.75
Current: 189.13
76.42
214.75
3-Year Total Revenue Growth Rate 21.20
3-Year Revenue Growth Rate ranked lower than
64.29% of 182 companies
in the Diagnostics & Research industry.
Industry Max: 371, Med: 4.8, Min: -100
PRAH: 19.2
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: 9.75, Max: 27.8
Current: 19.2
0
27.8
3-Year Total EBITDA Growth Rate 17.50
3-Year EBITDA Growth Rate ranked lower than
63.48% of 178 companies
in the Diagnostics & Research industry.
Industry Max: 141.7, Med: 10.1, Min: -340.1
PRAH: 15.6
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: 9.15, Max: 41.4
Current: 15.6
0
41.4
3-Year EPS w/o NRI Growth Rate 21.60
3-Year EPS w/o NRI Growth Rate ranked lower than
100.00% of 163 companies
in the Diagnostics & Research industry.
Industry Max: 138.7, Med: 10.1, Min: -301
PRAH: 21.6
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: 0, Max: 21.6
Current: 21.6
0
21.6

» PRAH's 30-Y Financials

Financials (Next Earnings Date: 2019-08-02)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:PRAH

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Medical Diagnostics & Research » Diagnostics & Research    NAICS : 621511    SIC : 8731
Compare NYSE:CRL NAS:BRKR NAS:GH NAS:ICLR MIL:DIA XPAR:ERF NAS:SYNH NYSE:QGEN NYSE:BIO SHSE:603658 SZSE:300676 XPAR:BIM NAS:NEOG NAS:QDEL NAS:GHDX NYSE:PKI SHSE:603882 NAS:MYGN BSP:DASA3 NAS:MEDP
Traded in other countries 8PH.Germany
Address 4130 ParkLake Avenue, Suite 400, Raleigh, NC, USA, 27612
PRA Health Sciences is a global contract research organization that provides drug development and clinical testing services to pharmaceutical and biotechnology companies. Its services run from early- to late-stage clinical trial outsourcing with varying levels of support, including one-off specialized staffing services to strategic partnerships where PRA handles nearly all aspects of the trial.

Ratios

Current vs industry vs history
PE Ratio (TTM) 41.22
PE Ratio ranked lower than
84.96% of 113 companies
in the Diagnostics & Research industry.
Industry Max: 1345, Med: 35, Min: 0.33
PRAH: 41.22
Ranked among companies with meaningful PE Ratio only.
PE Ratio range over the past 10 years
Min: 29.4, Med: 49.21, Max: 855.8
Current: 41.22
29.4
855.8
Forward PE Ratio 19.76
Forward P/E ranked higher than
65.00% of 40 companies
in the Diagnostics & Research industry.
Industry Max: 78.74, Med: 9999, Min: 11.64
PRAH: 19.76
Ranked among companies with meaningful Forward P/E only.
N/A
PE Ratio without NRI 41.22
PE without NRI ranked lower than
84.96% of 113 companies
in the Diagnostics & Research industry.
Industry Max: 1345, Med: 35.56, Min: 0.34
PRAH: 41.22
Ranked among companies with meaningful PE without NRI only.
PE without NRI range over the past 10 years
Min: 29.4, Med: 49.21, Max: 855.8
Current: 41.22
29.4
855.8
Price-to-Owner-Earnings 30.39
Price-to-Owner-Earnings ranked lower than
93.42% of 76 companies
in the Diagnostics & Research industry.
Industry Max: 1523.53, Med: 36.75, Min: 4.91
PRAH: 30.39
Ranked among companies with meaningful Price-to-Owner-Earnings only.
Price-to-Owner-Earnings range over the past 10 years
Min: 22.82, Med: 43.88, Max: 219.53
Current: 30.39
22.82
219.53
PB Ratio 5.93
PB Ratio ranked lower than
66.94% of 245 companies
in the Diagnostics & Research industry.
Industry Max: 270, Med: 4.02, Min: 0.15
PRAH: 5.93
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 1.95, Med: 5.02, Max: 7.78
Current: 5.93
1.95
7.78
PS Ratio 2.27
PS Ratio ranked higher than
65.22% of 230 companies
in the Diagnostics & Research industry.
Industry Max: 6350, Med: 3.81, Min: 0.07
PRAH: 2.27
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 0.87, Med: 2.05, Max: 2.76
Current: 2.27
0.87
2.76
Price-to-Free-Cash-Flow 23.87
Price-to-Free-Cash-Flow ranked lower than
61.25% of 80 companies
in the Diagnostics & Research industry.
Industry Max: 1356.19, Med: 29.22, Min: 0.35
PRAH: 23.87
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Price-to-Free-Cash-Flow range over the past 10 years
Min: 19.03, Med: 30.04, Max: 318.38
Current: 23.87
19.03
318.38
Price-to-Operating-Cash-Flow 19.48
Price-to-Operating-Cash-Flow ranked lower than
59.79% of 97 companies
in the Diagnostics & Research industry.
Industry Max: 1739.7, Med: 19.94, Min: 0.35
PRAH: 19.48
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 15.26, Med: 22.96, Max: 55.3
Current: 19.48
15.26
55.3
EV-to-EBIT 25.58
EV-to-EBIT ranked lower than
72.03% of 118 companies
in the Diagnostics & Research industry.
Industry Max: 341.21, Med: 25.06, Min: 5.74
PRAH: 25.58
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: 19.3, Med: 27.7, Max: 47.9
Current: 25.58
19.3
47.9
EV-to-EBITDA 18.41
EV-to-EBITDA ranked lower than
64.39% of 132 companies
in the Diagnostics & Research industry.
Industry Max: 486.47, Med: 20.75, Min: 3.94
PRAH: 18.41
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: 13.1, Med: 18.35, Max: 29.4
Current: 18.41
13.1
29.4
EV-to-Revenue 2.55
EV-to-Revenue ranked higher than
63.64% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 19679, Med: 4.24, Min: 0.09
PRAH: 2.55
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 1.5, Med: 2.5, Max: 3.3
Current: 2.55
1.5
3.3
Current Ratio 0.90
Current Ratio ranked lower than
91.20% of 250 companies
in the Diagnostics & Research industry.
Industry Max: 97.84, Med: 2.58, Min: 0.02
PRAH: 0.9
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.83, Med: 1.05, Max: 1.25
Current: 0.9
0.83
1.25
Quick Ratio 0.90
Quick Ratio ranked lower than
85.60% of 250 companies
in the Diagnostics & Research industry.
Industry Max: 97.84, Med: 2.14, Min: 0.02
PRAH: 0.9
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.83, Med: 1.05, Max: 1.25
Current: 0.9
0.83
1.25
Days Sales Outstanding 58.18
Days Sales Outstanding ranked lower than
58.82% of 204 companies
in the Diagnostics & Research industry.
Industry Max: 521.64, Med: 67.51, Min: 1
PRAH: 58.18
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 55.28, Med: 61.77, Max: 73.71
Current: 58.18
55.28
73.71
Days Payable 11.45
Days Payable ranked lower than
93.58% of 187 companies
in the Diagnostics & Research industry.
Industry Max: 981.81, Med: 63.34, Min: 1
PRAH: 11.45
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 8.83, Med: 14.25, Max: 18.53
Current: 11.45
8.83
18.53

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -3.30
3-Year Share Buyback Rate ranked higher than
72.78% of 180 companies
in the Diagnostics & Research industry.
Industry Max: 3.4, Med: -7.9, Min: -1732.6
PRAH: -3.3
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -3.3, Med: -2.3, Max: -1.7
Current: -3.3
-3.3
-1.7

Valuation & Return

Current vs industry vs history
Price-to-Projected-FCF 2.58
Price-to-Intrinsic-Value-Projected-FCF ranked lower than
100.00% of 75 companies
in the Diagnostics & Research industry.
Industry Max: 449, Med: 2.41, Min: 0.47
PRAH: 2.58
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 2.57, Med: 3.03, Max: 3.18
Current: 2.58
2.57
3.18
Price-to-Median-PS-Value 1.11
Price-to-Median-PS-Value ranked lower than
71.50% of 193 companies
in the Diagnostics & Research industry.
Industry Max: 7.22, Med: 1.01, Min: 0.01
PRAH: 1.11
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.47, Med: 1.01, Max: 1.29
Current: 1.11
0.47
1.29
Price-to-Peter-Lynch-Fair-Value 1.65
Price-to-Peter-Lynch-Fair-Value ranked lower than
100.00% of 30 companies
in the Diagnostics & Research industry.
Industry Max: 15.31, Med: 2.01, Min: 0.83
PRAH: 1.65
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
Price-to-Peter-Lynch-Fair-Value range over the past 10 years
Min: 1.59, Med: 1.72, Max: 1.85
Current: 1.65
1.59
1.85
Earnings Yield (Joel Greenblatt) % 3.90
Earnings Yield (Greenblatt) ranked higher than
67.55% of 265 companies
in the Diagnostics & Research industry.
Industry Max: 17.42, Med: -0.98, Min: -1428.57
PRAH: 3.9
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: 2.1, Med: 3.6, Max: 5.2
Current: 3.9
2.1
5.2
Forward Rate of Return (Yacktman) % 22.08
Forward Rate of Return ranked lower than
100.00% of 70 companies
in the Diagnostics & Research industry.
Industry Max: 7802.99, Med: 8.45, Min: -35.9
PRAH: 22.08
Ranked among companies with meaningful Forward Rate of Return only.
Forward Rate of Return range over the past 10 years
Min: 21.7, Med: 22, Max: 22.4
Current: 22.08
21.7
22.4

More Statistics

Revenue (TTM) (Mil) $ 2,892.11
EPS (TTM) $ 2.39
Beta 1.55
Volatility % 44.13
52-Week Range $ 82.12 - 121.98
Shares Outstanding (Mil) 65.66

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 7
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy N